Milestone Pharmaceuticals Inc. (MIST) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Milestone Pharmaceuticals reported revenue of $0. Net income was -$63.1M, or -$0.75 per diluted share. Operating activities generated -$49.0M of cash, leaving -$49.3M of free cash flow. At fiscal year end, Milestone Pharmaceuticals held $113.6M in total assets against $71.8M in total liabilities, including $73.0M of cash and equivalents.
Open the full interactive Milestone Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Milestone Pharmaceuticals Key Stats
| Share Price | $0.77 |
|---|---|
| 52-Week Range | $0.71 – $2.95 |
| Shares Outstanding | 41.3 million (basic, 2021 Q1) |
Milestone Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$50.7M | -$43.1M | -$59.6M | -$61.1M | -$42.1M | -$62.1M |
| Pre-Tax Income | -$50.0M | -$42.9M | -$58.4M | -$59.7M | -$41.5M | -$63.1M |
| Income Tax | -$17,000 | — | — | — | — | — |
| Net Income | -$50.0M | -$42.9M | -$58.4M | -$59.7M | -$41.5M | -$63.1M |
| Diluted EPS | -$1.70 | -$1.02 | — | -$1.39 | -$0.67 | -$0.75 |
Milestone Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $238,000 | $559,000 |
| Net Income | -$11.9M | -$17.4M | -$26.1M | -$28.6M |
| Diluted EPS | -$0.12 | — | -$0.20 | -$0.21 |
Milestone Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $72.3M | $114.1M | $7.6M | $13.8M | $25.3M | $73.0M |
| Current Assets | $148.7M | $118.9M | $71.8M | $73.0M | $73.9M | $111.9M |
| Total Assets | $150.0M | $119.8M | $74.5M | $75.2M | $75.5M | $113.6M |
| Current Liabilities | $6.2M | $6.8M | $6.1M | $7.2M | $8.1M | $14.0M |
| Total Long-Term Debt | — | — | — | $49.8M | $53.4M | $57.2M |
| Total Liabilities | $6.9M | $7.2M | $8.1M | $58.5M | $62.4M | $71.8M |
| Shareholders' Equity | $143.1M | $112.6M | $66.3M | $16.8M | $13.1M | $41.8M |
Milestone Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$50.7M | -$33.2M | -$52.5M | -$46.4M | -$28.8M | -$49.0M |
| Cash From Investing | -$70.0M | $70.0M | -$57.1M | $4.8M | $8.3M | $11.2M |
| Cash From Financing | $73.2M | $5.1M | $3.1M | $47.8M | $32.1M | $85.5M |
| Free Cash Flow | -$51.1M | — | -$52.7M | -$46.5M | -$28.9M | -$49.3M |
Figures from Milestone Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Milestone Pharmaceuticals financials page for every line item.
Milestone Pharmaceuticals Company Profile
| Ticker | MIST |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Montreal, Quebec, Canada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001408443 |
Frequently Asked Questions
What was Milestone Pharmaceuticals' revenue in fiscal 2025?
Milestone Pharmaceuticals (MIST) reported revenue of $0 for fiscal 2025.
What is Milestone Pharmaceuticals' annual revenue history?
Milestone Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Milestone Pharmaceuticals' net income in fiscal 2025?
Milestone Pharmaceuticals reported net income of -$63.1M for fiscal 2025.
What was Milestone Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Milestone Pharmaceuticals' diluted EPS was -$0.75 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Milestone Pharmaceuticals generate in fiscal 2025?
Milestone Pharmaceuticals generated -$49.3M of free cash flow in fiscal 2025.
What was Milestone Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Milestone Pharmaceuticals reported revenue of $559,000.
How much debt does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals reported $57.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Milestone Pharmaceuticals are outstanding?
Milestone Pharmaceuticals reported a weighted average of 41.3 million basic shares outstanding in 2021 Q1.
When does Milestone Pharmaceuticals' fiscal year end?
Milestone Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Milestone Pharmaceuticals headquartered?
Milestone Pharmaceuticals lists its business address in Montreal, Quebec, Canada in its SEC filings.